GlassScriptPhysician profile
Wei Zhu
NPI 1104234863
$3,084.19
in general payments reported to CMS, 2019-2025
24 companies · $998 in 2025
The $998 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.77 · 2022: $142 · 2023: $811 · 2024: $1,093 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,797 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,796.66 |
| Education | $105.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $613.19 | 2021-2025 | Jakafi, Jakafi, Niktimvo |
| Astellas Pharma US INC | $373.10 | 2023-2025 | Xospata, Cresemba |
| Astrazeneca Pharmaceuticals LP | $304.34 | 2022-2025 | Calquence |
| Lilly USA, LLC | $268.98 | 2023-2025 | Jaypirca |
| Celgene Corporation | $188.00 | 2022-2025 | Reblozyl |
| Sobi, INC | $158.10 | 2024-2025 | |
| Blueprint Medicines Corporation | $154.38 | 2023-2024 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $135.92 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $132.38 | 2023-2025 | Reblozyl, Keytruda, Dificid |
| Syndax Pharmaceuticals, INC. | $131.14 | 2025 | |
| Adaptive Biotechnologies Corporation | $117.72 | 2025 | Clonoseq |
| Daiichi Sankyo INC. | $82.91 | 2023-2024 | Vanflyta |
| Pharmaessentia USA Corporation | $79.01 | 2023 | Besremi |
| Rigel Pharmaceuticals, INC. | $62.55 | 2023-2025 | Rezlidhia, Gavreto, Tavalisse |
| Pacira Pharmaceuticals Incorporated | $33.98 | 2023 | Exparel |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $33.66 | 2024 | |
| Glaxosmithkline, LLC. | $30.06 | 2024 | Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $29.79 | 2025 | Iclusig |
| Amgen INC. | $27.54 | 2023 | Blincyto |
| Janssen Biotech, INC. | $27.54 | 2024 | Imbruvica |
| Cti Biopharma Corp. | $27.00 | 2023 | Vonjo |
| Abbvie INC. | $26.61 | 2024 | |
| Servier Pharmaceuticals LLC | $24.62 | 2022 | |
| Beigene USA, INC. | $21.67 | 2024 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Zhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.